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ABSTRACT 
 
Introduction: Numerous studies have confirmed the association between the delivered 
dose of haemodialysis and patients outcomes. There is thus some evidence regarding the 
relationship between dialysis dose and quality of life.   
 
Objective:  The study was designed to assess dialysis adequacy using urea kinetic 
modelling parameters and to determine the association between dialysis dose and patient 
outcomes. 
 
Methods:  A retrospective review of the demographic and biochemical data of 61 patients 
on chronic haemodialysis in the year 2003 was performed and a prospective component 
was added to the study for quality of life and evaluation of cardiovascular comorbidity. 
 
Results:   The mean delivered dose Kt/V was 1.34 ± 0.25. There was a statistically 
significant correlation (p<0.05) between dialysis dose and the following parameters: 
haemoglobin, physical dimension and its 3 scales, the SF-36 overall score, as well as 
between dialysis dose and sepsis. 
 
Conclusion: The dialysis dose correlated with a significant number of parameters 
including Hb and the physical components of the SF-36; hence, the importance of 
measuring the delivered dialysis dose of patient on maintenance dialysis in accordance 
with DOQI guidelines for improved patient outcomes is confirmed. 
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1.1. History of dialysis 
 
Dialysis is a Greek word meaning "loosening from something else"; it is derived from the 
Greek dia (= through); and leuin (= to loosen); (Davison, 1998).  
Nevertheless, it was the Romans who first used a form of dialysis therapy by giving hot 
baths to patients to remove urea. The action of the hot water made the patient sweat 
profusely and, this together with water removal resulted in removal of the toxins. Diffusion 
of toxins through the skin into the bath water would temporarily relieve symptoms. This 
treatment was still on occasions used into the 1950s, as the only hope.  
Dialysis is not a recent discovery; in 1854 Thomas Graham a Scottish chemist (Graham, 
1854) was the first to use the term `dialysis`. He demonstrated that 'crystalloids', but not 
'colloids', diffused down a concentration gradient across a semi-permeable membrane 
separating two solutions (Davison, 1998; Nissenson et al, 1990). The membranes were 
made from a variety of substances, including parchment and colloidion (Eggrth, 1921) 
       
In 1913, Abel Rowntree and Turner at the John Hopkins Medical School in Baltimore 
wrote the first article on the technique of haemodialysis, named the artificial kidney. 
Experimental dialysis was performed on nephrectomized dogs, by using variances in the 
composition of dialysis fluid (Abel et al, 1914). The main aim was the removal of 
salicylates. The removal of fluid and toxins that accumulated due to kidney disease were 
not at this time considered. However, difficulties in dialysis construction and 
anticoagulation control prevented further developments for about 7 years. Hirudin was the 
first anticoagulant used. In 1920, Georg Haas in Gissen, Germany performed the first 
dialysis on a human, in a uraemic patient. Hand-made colloidion membranes were used 
and clotting was prevented by using Hirudin and, later, a crude form of heparin. Haas used 
multiple dialysers to increase the surface area of blood exposed to the dialysis fluid, but the 
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arterial pressure of the blood was insufficient to propel the blood through the entire 
extracorporeal circuit. He therefore introduced a pump into the circuit (Smith et al, 2002, 
p3). George Haas was consequently honoured as the pioneer of dialysis. As his institution 
and his colleagues did not support him, he gave up and the work was stopped. 
       
Despite all the above developments, until 1940, patients with uraemic symptoms could be 
offered nothing more than bed rest and salt free diet composed mainly of vegetables, 
carbohydrates and fat to reduce protein metabolism. Nevertheless, the American scientist 
William Thalhimer worked on the use of cellophane and the purification of heparin 
(Thalhimer, 1938). These two advances gave rise to the next stage of development, which 
took place between 1940-1950. 
 
Willem Kolff, a physician working in Groningen in Nazi-occupied Holland, built a rotating 
drum dialyser, which provided sufficient surface for human haemodialysis. After the war 
in 1945, Kolff`s technique was widely used, particularly in Sweden and the United States 
of America .The treatment was mainly used for acute renal failure when kidney function 
could be expected to return to normal, following a short period of dialysis treatment; it was 
just a bridging dialysis (Kolff, 1950). 
 
 For his great contribution, Willem Kolff is the acknowledged father of modern kidney 
dialysis. However vascular access limited dialysis to patients with acute renal failure who 
only needed renal replacement therapy for a short period of time (Kolff et al, 1965) 
 
Thereafter, the rotating drum dialyser was modified by Dr Carl Walter, at the Brent 
Brigham Hospital together with Edward Olson, an engineer from Renwal, to create a new 
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version of the Kolff device, the Kolff-Brigham kidney dialysis machine and over 40 of 
these machines were built and exported all over the world. 
 
Jack Leonards and Leonard Skeggs produced a plate dialyser, which permitted a reduction 
in the priming volume and allowed negative pressure to be used to remove fluid from the 
patient’s system (Skeggs et al., 1949). Larger dialysers followed, which necessitated the 
introduction of a blood pump. 
 
It was in the late 1950s when Fredrik Kiil of Norway developed a parallel plate dialyser 
with a large surface area (1 m2) requiring a low priming volume (Smith et al, 2002, p8).  
 
Finally, Baxter was the first to manufacture a commercial dialyser, which was based on the 
Kolff kidney. It was the equivalent to today's dialysers and was on the coil design. It 
provided a urea clearance of approximately 140 ml/min. In 1960, Richard Stewart 
produced the true forerunner of today's capillary flow dialyser. It was a hollow-fibre 
dialyser with a low priming volume and minimal resistance to flow. 
 
The vascular access problem for chronic patients was solved by Scribner's shunt and 
strongly promoted home dialysis in the United Kingdom. 
 
In 1960 in the USA, George Quinton, an engineer and Belding Scribner, a physician, 
created the arterio-venous (AV) shunt and James Cimino developed the subcutaneous 
radial artery to cephalic vein AV Fistula (Cimino & Brescia, 1962). 
 
  
 
 
14
Up-to-date, monitoring and total control of the patient's therapy became more important as 
dialysis became widespread, and so equipment development continued. Hence, the 
introduction of dialysis as a life saving treatment for kidney failure was not the result of 
any large-scale research program; rather it resulted from the activities of scientists, 
pioneers who were able to utilise ideas, materials and methods from a range of developing 
technologies. 
 
The 21st century has been set to enhance dialysis adequacy, in attempts to improve 
patients’ quality of life. Good nutrition has also emerged as playing a vital role in reducing 
dialysis morbidity and mortality. World- wide, currently more than 500 000 people are 
undergoing haemodialysis treatment.       
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1.2. Dialysis adequacy 
       
1.2.1. Definition 
 
Dialysis adequacy is the recommended quantity of haemodialysis delivered which is 
required for adequate treatment of end stage renal disease (ESRD), such that the patient 
receives full benefit of haemodialysis (RPA, 1993). Adequacy of haemodialysis is an 
important determinant of patient morbidity and survival. 
 
To ensure that ESRD patients treated with chronic haemodialysis receive a sufficient 
amount of dialysis, the delivered dose should be measured and monitored routinely and 
regularly. 
 
1.2.2. Parameters considered for assessment of dialysis adequacy 
 
Simply following the blood urea nitrogen (BUN) is insufficient because a low BUN can 
reflect inadequate nutrition rather than sufficient dialytic urea removal. Furthermore, to 
monitor the patients’ symptoms alone is not sufficient i.e. the combination of dialysis plus 
erythropoietin to correct anaemia can eliminate most uraemic symptoms even if the patient 
is under-dialysed. 
 
Urea kinetic modelling is widely used in clinical practice to quantify and deliver adequate 
doses of dialysis, as reported by Gotch et al. 1975. Urea is the substance that is most often 
monitored in clinical practice as a surrogate for measurement of the clearance of small 
solutes. The reasons are that urea: 
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− Is a small readily dialysed solute that is the catabolite of dietary protein (Gotch, 1995; 
Yeun, 2000)[3, 4]? 
− Constitutes 90% of waste nitrogen accumulated in body water between haemodialysis 
treatments (Gotch, 1995; Yeun et al, 2000). 
− Is easily measured in blood, and the fractional clearance of urea in body water 
correlates with patient outcomes, such as mortality and morbidity (Hakim et al, 1994; 
Lowrie et al, 1981; Lowrie, 1994). 
Furthermore urea is unequivocally recognised as a marker of solute retention and removal 
in dialysed patients. The degree of urea clearance correlates with clinical outcomes of 
patients undergoing maintenance haemodialysis (Fernandez, 1992). Thus, urea kinetic 
modelling is used to estimate and, if necessary, to provide the correct dialysis dose. 
 
Conventional methods of quantifying the prescribed or delivered haemodialysis dose 
began by estimating the difference in predialysis and postdialysis urea concentration by 
sampling patients before and after a single dialysis session. According to DOQI 
guidelines, the practice of sampling to measure the haemodialysis dose consists of slowing 
the blood pump to 50 ml/min and to obtain the blood sample for BUN estimation 15 
seconds later (Silvester, 1997). This earlier measurement is thought to be the most 
accurate method to support formal kinetic modelling, and to ensure consistent values; the 
measurement of the postdialysis BUN should be performed in exactly the same way each 
time it is assessed (NKF-DOQI guidelines)     
 
The adequate delivered dose of solute removed is assessed by the following parameters:  
1.2.2.1. Kt/V :  
K: Dialyser urea clearance supplied by the manufacturer in litres per minute (l/min) 
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t: The duration of dialysis in minutes(min). 
V: The volume of distribution of urea in litres (l).   
 
Kt/V is calculated as follows:  
 
 
• Ln  is the natural logarithm 
• R is the  postdialysis BUN ÷ predialysis BUN 
• t is the length of the dialysis session in hours 
• UF is the ultrafiltration volume in litres 
• W is the patient's postdialysis weight in kilograms 
 
As per the above formula, the value of Kt/V should be at least 1.3 for stable patients 
dialysed thrice weekly (DOQI guidelines, 2000). This is important to prevent the delivered 
dose of HD from falling below the recommended dose. 
 
In terms of URR, (urea reduction ratio) a Kt/V of 1,3 corresponds to an average URR of 
70%. However the URR corresponding to a Kt/V of 1.3 can vary substantially as a 
function of ultrafiltration. Different target values are needed for patients who are dialysed 
more or less frequently.  
Nevertheless, because of the complexity of the formulae to calculate the Kt/V by UKM 
there are other methods to calculate it in order to assess dialysis adequacy, such as 
In which: 
W
UFRtRLnVKt ××−+×−−= )5.34()008.0(/
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computer models and statistical models. Moreover, there are other alternative methods for 
calculating Kt/V for assessing adequacy. These include:  
 
1.2.2.2.  The timed average urea concentration (TACurea): It has been suggested that 
the timed average urea concentration is preferable to Kt/V because it also measures urea 
generation, thereby allowing the estimation of the PCR (Held, 1996). The TACurea has a 
major limitation in that poor nutrition often due to inadequate dialysis may lead to a low 
predialysis BUN and therefore to a low TACurea that misleadingly suggests adequate 
dialysis. It is the reason why TACurea must be evaluated in concert with the protein 
catabolic rate which estimates protein intake.       
    
 
 
• C1 and C2 are the predialysis and postdialysis BUN 
• C3 is BUN at the beginning of the next dialysis 
• Td is the dialysis time 
• Id is the interval between the two dialyses 
 
A TACurea of 50 mg/dl is roughly equivalent to a Kt/V of 1.2 (Held, 1996). According to 
the National Cooperative Dialysis Study (Held et al, 1996), dialysed patients with 
TACurea of 52 mg/dl have a better outcome than patients with TACurea of 100 mg/dl.   
 
Where: 
[ ]( ) [ ]( )
( )IdTd2
C3C2IdC2C1TdTACurea
+×
+×++×
=
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1.2.2.3.  Solute removal index: This is another method of measuring dialysis adequacy. 
With this method, the total amount of urea removed during haemodialysis is measured by 
multiplying urea concentration in the dialysate by the volume of used dialysate. However 
the DOQI clinical workgroup for haemodialysis adequacy has been focusing their 
recommendations exclusively on blood-based measures of adequacy. Thus, studies are 
lacking that correlate patient outcomes with the values obtained with this index. 
 
1.2.2.4.  Non-normalised dialysis dose (Kt): The correction of total urea removal (Kt) for 
the volume of distribution resulting in Kt/V is important. However, according to Kt/V 
formulae it is assumed that V does not alter patient outcomes despite its effect on the 
clearance of urea. This is important because some evidence suggest that the assumption is 
not true. For example, black dialysis patients, although they have a relatively lower URR, 
have superior survivals compared with white patients (Owen et al, 1998). A retrospective 
study of more than 17,000 haemodialysis patients showed that increasing Kt, independent 
of body size was associated with a lower risk of mortality. Further studies are required to 
determine whether the Kt alone is a superior measure of dialysis dose. 
 
1.2.2.5. Urea Reduction Ratio (URR): The HD adequacy work group acknowledges the 
ease of calculation of URR (Baltimore, 1998; Bethesda, 1996). 
In fact of the three methods for measuring haemodialysis adequacy and the delivered dose 
of haemodialysis, which are the Kt/V, the Protein catabolic rate (PCR) and the URR, the 
URR is the simplest to use.  
 
100
BUNsPredialysi
BUNdialysisPostBUNsPredialysiURR ×−=
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The URR has been proven to be a statistically significant predictor of mortality for ESRF 
patients (Held, 1996; Owen et al, 1993). In contrast to formal urea kinetic modelling and 
the Kt/V natural logarithm formulae (Daugirdas, 1993; Depner, 1993; Sherman et al, 
1995), the URR does not account for the contribution of ultralfiltration to the final 
delivered dose of dialysis. This is because the convective transfer of urea that occurs by 
ultralfiltration does not result in a decrease in the BUN concentration, although urea 
removal into the dialysate has occurred. Thus the URR is less accurate in estimating the 
delivered dose of haemodialysis than the Kt/V and the URR does not take into 
consideration the contribution of residual kidney function to urea clearance. 
 
Furthermore there is a curvilinear relationship between Kt/V and URR, hence a URR of 
65% corresponds to a Kt/V of 1.2 and URR of 70% is equivalent to a Kt/V of 1.3. 
According to the DOQI guidelines, a URR should be at least 70% (Sehgal et al, 1998).  
 
1.2.2.6. Protein Catabolic Ratio (PCR ) 
 The PCR is also called the protein equivalent of nitrogen appearance (PNA). It is used in 
most HD units to assess dietary protein intake in patients who are in a steady state 
regarding nutritional status, as it is a function of protein intake which should reflect 
dialysis adequacy. 
 
The PCR is determined by measuring the interdialytic appearance of urea in body fluids 
plus any urea lost in urine in patients with residual renal function. The PCR is of value in 
prospectively predicting morbidity in haemodialysis patients (Laird et al, 1983). 
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The PCR is usually expressed as g/kg per day, a parameter that is also called the 
normalised PCR (nPCR). Less commonly, the PCR is not normalised to weight and is 
expressed as g/day.   
  
The National Cooperative Dialysis Study (NCDS) recommended a minimal nPCR of 
0.8g/kg per day (Laird et al, 1983), but a target of 1.0 to 1.2g/kg per day or higher is 
currently recommended (Dumler et al, 1992; Gombe et al, 2000; Hakim, 1990). 
Formal UKM permits calculation of the nPCR. The volume of distribution term may be 
used to calculate the nPCR as follows: 
 
 
More importantly, the nPCR can be useful to identify patients who might benefit from 
counselling about their dietary protein intake. Furthermore, it is used as a marker of HD 
adequacy. In the NCDS, a PCR greater than 1g/Kg/day has been associated with low 
morbidity and mortality (Laird et al, 1983). 
DOQI guidelines recommend nPCR of at least 0.8g/kg per day. The ideal, being nPCR 
value between 1g/kg per day to 1.2gr/kg per day. 
 
1.2.2.7.  Other parameters of dialysis adequacy:  
There are other parameters, which are suggestive of dialysis adequacy:  
− Predialysis BUN between 25 to 32 mmol/L 
− Low requirement for erythropoietin and antihypertensive drugs 
− Plasma albumin greater than 40 g/L 
nV/0.58)g/day)(mea(PCR,day)nPCR(g/kg/ =
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− Predialysis plasma creatinine concentration more than 1100 µmol/L 
(Bommer, 2001; Iseki, 1993; Lowrie et al, 1990; Owen et al, 1993). 
The improved outcome associated with higher plasma creatinine 
concentration is probably a reflection of muscle mass and adequate 
nutrition. 
− Interdialytic weight gain  
− Haemoglobin level 
− Serum parathormone level 
− Dialysis session time more than 4 hours 
− Number of hospitalisations  
1.2.3. Frequency of measurement of haemodialysis adequacy  
 
To ensure that ESRD patients treated with chronic HD receive a sufficient amount of 
dialysis, the delivered dose should be measured and monitored routinely by every 
haemodialysis unit; the NKF-DOQI guidelines recommend an assessment of the 
haemodialysis dose once per month for stable patients haemodialysed thrice weekly for at 
least for four hours per session.  
 
However, the frequency of measurement of the delivered dose of haemodialysis should be 
increased when: 
− Patients are non-compliant with their haemodialysis prescriptions (missed 
treatments, late for treatments, early sign-off from haemodialysis treatment). 
− Frequent problems are noted in delivery of prescribed dose of haemodialysis 
(such as variable poor blood flow rates, or treatment interruptions because of 
hypotension or angina pectoris).  
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− Wide variability in urea kinetic modelling results is observed in the absence of 
prescription changes. 
− The haemodialysis prescriptions are modified.  
 
Dialysis adequacy impacts on outcomes of patients on dialysis as discussed previously. 
Other independent predictors of dialysis outcomes include: 
− Primary renal disease: Evidence has shown the best survival in 
haemodialysis patients with chronic glomerular diseases and polycystic kidney 
disease, intermediate survival in ESRD secondary to hypertension and the 
worst survival with diabetic nephropathy (Mailloux et al, 1994; USRDS, 
1998).   
− Comorbid conditions: The presence of comorbid conditions is a common 
problem in haemodialysis patients; left ventricular hypertrophy, metabolic 
abnormalities, atherosclerosis, dyslipidaemia, diabetes affects overall survival 
(Ganesh et al, 2001). 
− Age: Studies have shown that survival declines with increasing age (Chara et 
al, 1992; Mailloux et al, 1994). 
− Race: African-Americans and Asian-Americans have a lower mortality rate 
than whites (Daugirdas, 1998; Tanna et al, 2000, Wong et al, 1999). This 
finding persists even after adjustment of patient characteristics, comorbidities 
and laboratory values. There is no data on this in South Africa.    
− Psychosocial factors: Increased level of social support results in enhanced 
compliance and good acceptance of the illness have been associated with lower 
relative risk of mortality (Kimmel et al, 1998). 
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− Nutrition: Increased mortality and morbidity have been observed in under-
nourished patients as evidenced by different levels of hypoalbuminemia. 
Furthermore, the presence of malnutrition prior to the initiation of dialysis is 
strongly predictive of increased mortality. 
1.2.4. Pitfalls in measuring dialysis adequacy 
 
Urea kinetic modelling is probably the most objective way of measuring dialysis adequacy. 
In fact, urea is unequivocally recognised as a marker of solute retention and removal in 
dialysed patients. The degree of urea clearance also correlates with clinical outcomes of 
patients on maintenance haemodialysis. 
 
However, high blood concentration of urea may not necessarily correlate with poor 
outcomes in certain circumstances: 
− High serum concentrations of urea due to adequate protein intake that are 
compensated by adequate removal is a marker of adequate dialysis and is 
different from the high urea levels secondary to inadequate dialysis 
(Blumenkrantz, 1982). 
− Low urea levels related to poor nutrition reflect dialysis inadequacy and may 
negatively affect the patient prognosis (Lowrie et al, 1990).  
 
It has also been suggested that the kinetics of urea is representative of the behaviour of 
other uraemic toxins. However, data suggests that the dialytic removal of lipophilic 
protein-bound compounds, as well as that of several other water-soluble compounds, is 
different from that of urea (Lesaffer et al, 2000; Vanholder et al, 1992).   
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Some investigators have therefore asked whether there should be a search for marker 
molecules that are representative of middle, large or lipid-soluble compounds. In fact the 
haemodialysis work group recognises that an increasing body of evidence suggests that the 
clearance of larger molecular weight solutes may have an independent effect on patient 
survival that is not fully reflected in the Kt/Vurea .    
 
In addition, many different factors influence the correct determination of Kt/V such as urea 
sequestration in different body compartments, vascular access and cardiopulmonary 
recirculation. These factors, together with the single-pool instead of the double-pool effects 
are responsible for urea rebound after the end of haemodialysis sessions causing poor Kt/V 
estimation.  
 
Furthermore, some patients with residual renal function may have significant urea loss 
from the native kidneys. This should be measured and added to the measured Kt/V to 
achieve an effective Kt/V.  
 
1.3. Why is dialysis adequacy important? 
 
Uncontrolled observations suggest that increasing the intensity of dialysis to achieve a 
Kt/V of at least 1.3 is associated with improved survival, which is the Kt/V value 
recommended by the DOQI guidelines. 
 
Furthermore, numerous outcome studies have shown a correlation between the delivered 
dose of haemodialysis and patient morbidity and mortality (Collins et al, 1994; Fernandez 
et al, 1992; Gotch et al, 1997; Hakim et al, 1994; Held et al, 1996; Lowrie et al, 1981; 
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Lowrie, 1994; Owen et al, 1993; Owen et al, 1998; Parker et al, 1994). The evidence 
demonstrates that mortality among ESRF patients is lower when sufficient haemodialysis 
treatments are provided. This can be explained by the fact that dialysis efficiency has been 
related to better control of arterial blood pressure, anaemia and serum phosphorus levels, 
and to improvement in patients’ nutritional status.    
 
Figure 1 SHOWING THE CORRELATION BETWEEN DIALYSIS DOSE AND 
PATIENT SURVIVAL 
 
 
1.4. Nutritional status in haemodialysis patients. 
 
Malnutrition is an important problem in patients treated with chronic haemodialysis. 
The most common cause of inadequate nutrition in many patients is underdialysis, which 
can lead to decreased food intake because of diminished appetite, vomiting.  
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Evidence has shown that dialysis adequacy and nutrition have an effect on mortality and 
morbidity. It has been observed that the presence of malnutrition prior to the initiation of 
dialysis is strongly predictive of increased mortality with dialysis (Chung et al, 2000). 
Studies have also demonstrated that, unlike the general population, there was no positive 
correlation between blood pressure and body mass index (B.M.I); thus underweight rather 
than overweight is associated with a higher prevalence of hypertension. Therefore, 
assessment of the adequacy of dialysis necessitates the evaluation of patients’ nutritional 
status.  
 
Protein-energy malnutrition (PEM) is very common in patients undergoing maintenance 
dialysis. Different reports suggest the prevalence of this condition to be between 18 % to 
70% in adults on maintenance HD. In adults the presence of PEM is one of the strongest 
predictors of morbidity and mortality. 
 
There are many causes of PEM in patients with advanced chronic renal failure (CRF). 
These include: 
− Inadequate food intake secondary to: anorexia caused by the uraemic state, altered 
taste sensation. It has also been postulated that hyperleptinaemia observed in 
patients with end stage renal failure may contribute to anorexia and malnutrition 
(Daschner et al, 1998; Fouque et al, 1998; Johansen et al, 1998). 
− Uraemia is a catabolic state associated with  frequent illnesses, and a state of 
chronic inflammation 
− The dialysis procedure itself may remove nutrients i.e. amino acids, peptides, 
protein, glucose , water-soluble vitamins; protein catabolism due to bio-
incompatibility of the dialysis membranes  
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− Medications such as phosphate binders can impair nutrient absorption. 
− Other factors predisposing to malnutrition in haemodialysis patients include 
gastroparesis (for example, in diabetic patients) (Rothstein et al, 1992), which in 
some cases do not respond to increases of the dialysis dose. Gastroparesis may 
occur in non-diabetic patients on maintenance haemodialysis (De Schoenmakere et 
al, 2001; Grodstein et al, 1979). 
   
In order to prevent PEM in patients on MHD, the provision of adequate nutrition is 
important. Nutritional status should be evaluated periodically. 
 
The methods used to assess nutritional status: 
 
1. History and physical examination can provide important clues to the patient who might 
be malnourished: 
− Symptoms such as nausea, anorexia, weight loss or gain. 
− Concomitant problems such as alcoholism, DM, hyper- or hypothyroidism, GIT 
pathologies etc may affect the nutritional status. 
− Socio-economic issues: financial problems, unemployment, signs and symptoms of 
depression which can result in disinterest and in a decrease in caloric intake.     
2. Patients’ food intake is an important component of the nutritional assessment 
(Wolfson, 1999). The protein intake can be estimated by calculating the PCR, utilising 
kinetic modelling (Hakim et al, 1993). The PCR is a reflection of protein intake only if 
the patient is in neutral nitrogen balance (Hakim et al, 1993).    
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3. Anthropometric measurements help to evaluate body fat and muscle mass. Body fat 
is estimated by measuring skin fold thickness at the triceps or subscapular areas, 
while mid-arm circumference can provide an estimate of the muscle mass. The 
results of these measurements are compared to reference standards obtained from 
healthy adults during the National Health and Nutrition Examination Surveys 
(NHANES II) from 1986 to 1980 (Table 1). Anthropometry has the advantage of 
being simple, non-invasive and quick to carry out. 
 
Table 1 Anthropometry in haemodialysis patients 
 
 
4. The nutritional status can also be assessed by bioelectric impedance analysis (BIA) 
and dual-energy x-ray absorptiometry (DEXA) (Segal et al, 1991; Vanitallie et al, 
1990) but they are reserved for selected patients because they are sophisticated 
techniques and not available in the majority of the health centres. Unfortunately, 
these techniques do not distinguish between fat mass and body water. 
 
5. Plasma protein measurements:  
Albumin: several studies have shown a negative correlation between the plasma 
albumin and mortality in patient on MHD (shown on Figure 1-2) (Goldwasser et al, 
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1993; Lowrie et al, 1990; Owen et al, 1993; Rocco et al, 1993; Teehan et al, 1990). 
However, albumin is not a specific marker of malnutrition as it is an acute phase 
protein with a half-life of 21 days; and hepatic stores are significant. Moreover, 
changes in extracellular volume represent a potential source of error in assessing the 
plasma albumin concentration.  
Figure 2 SHOWING CORRELATION BETWEEN PLASMA ALBUMIN 
CONCENTRATION AND MORTALITY IN PATIENT ON MHD 
 
 
 
The increase in mortality associated with hypoalbuminaemia is observed in 60 to 67 
percent of patients on chronic haemodialysis (Lowrie et al, 1990; Owen et al, 1993). 
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It appears to occur even with an almost normal serum albumin (35 g/L). However, 
the mortality is further increased with more severe hypoalbuminaemia (less than 30 
g/L). The DOQI guidelines recommend the measurement of albumin on a monthly 
basis (DOQI Guidelines, 2000).  
Like albumin, a significant number of plasma proteins can also be used to evaluate 
nutritional status:  
Transferrin concentration: Low transferrin levels have been described in dialysis 
patients and have been found to be associated with malnutrition (Buchwald et al, 
1989; Owen et al, 1993; Young et al, 1991). However, plasma transferrin levels may 
be decreased in renal failure and with erythropoietin therapy for the treatment of 
anaemia of renal failure. 
 
Prealbumin: Plasma concentrations of prealbumin may vary with the state of 
nutrition in patients with normal renal function. However as prealbumin is excreted 
and metabolised by the kidney, it tends to accumulate in renal failure (Cano et al, 
1988). It explains why a single value of prealbumin may not be an accurate indicator 
of nutrition, and serial measurements should be monitored once a baseline level has 
been established for the particular patient. Unlike albumin, prealbumin has a short 
half-life and changes rapidly in response to alterations in nutritional status. It has 
been found that a value below 30mg/dl is a parameter of malnutrition for patients on 
haemodialysis (Hakim et al, 1993). As per albumin, prealbumin is also an acute 
phase protein, and its value must be interpreted with caution in situations of acute 
inflammation.  
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Cholesterol: As cholesterol concentration is reduced in undernourished patients with 
normal renal function, it is also lower with end-stage renal disease. The evidence has 
shown an inverse relationship between mortality and cholesterol concentration 
(Degoulet et al, 1982; Lowrie et al, 1990). 
 
Blood urea nitrogen: Low predialysis BUN levels have been found to be associated 
with increased mortality (Hakim et al, 1993); low values of BUN related to decreased 
protein intake may be misleading in the prescription of dialysis dose causing 
underdialysis, which will then lead to worsening of the nutritional status, in view of 
loss of appetite and subsequently, to decline in protein intake; hence, the role of 
monitoring the protein catabolic rate in dialysis patients.     
 
Creatinine production: Creatinine is also a marker of nutrition as it is a product of 
muscle breakdown. Studies have shown a reduction in survival in patients on chronic 
haemodialysis with lower plasma creatinine concentration levels (Lowrie et al, 1990; 
Rocco et al, 1993; Teehan et al, 1990).  
 
A variable plasma amino acid pattern has been also found in end-stage renal disease. 
In general, the essential amino acids are decreased, while the nonessential amino 
acids are either within the normal range or increased (Bergstrom et al, 1990; Kopple 
et al, 1975). These changes may be due to uraemia itself, rather than reflecting 
malnutrition.  
 
Obviously there is no one measure which can be used to accurately assess patients’ 
nutritional status. Therefore, patients on chronic haemodialysis should undergo a 
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variety of measurements in order to develop a profile, which can be used to assess the 
nutritional status.   
1.5. Quality of life of patients on maintenance haemodialysis. 
 
Patients on maintenance haemodialysis often show a significant decrease in quality of 
life. Haemodialysis patients experience numerous symptoms in terms of medical 
outcomes and also in terms of potential reduction in functioning and wellbeing.     
 
In fact, despite technical progress in therapy, haemodialysis patients continue to report 
health- related quality of life, which is substantially lower than that of the general 
population. Patients often report that they are limited by their physical functioning and 
by multiple dialysis-related symptoms i.e. cramps, symptomatic hypotension, anaemia 
and other symptoms related to dysautonomia. Hence, patient perception of health is an 
important outcome measure in the assessment of the influence of chronic disease and 
its treatment. Moreover, perception of health-related quality of life influences 
compliance by the patients. 
 
Research findings from Europe and U S A demonstrated that patients who are treated 
with successful renal transplantation experience a quality of life, which is superior to 
that achieved with any dialysis modality and which is very close to the quality of life 
scores of the general population. 
     
Different studies have shown a better quality of life with predialysis clinic attendance. 
This may result from opportunities for patient education, dietary counselling, modality 
selection, permanent dialysis access creation and management of comorbid conditions 
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i.e. the importance of early predialysis correction of anaemia by the use of 
erythropoietin and iron management has been emphasised in different trials (Zehnder et 
al, 1992). In fact several studies have proved that earlier initiation of erythropoietin 
therapy may improve patient morbidity and mortality by retarding or preventing the 
development of cardiomyopathy secondary to anaemia.  The DOQI guidelines 
recommend an Hb between 11 to 12 g/l   
 
Furthermore, delayed diagnosis, late referral and delay in commencing dialysis are 
commonly observed in developing countries and also probably in the developed 
nations (Ratcliffe et al, 1984).  In fact, these patients have a higher frequency of 
clinical complications, metabolic disturbances, long term access problems and a higher 
mortality rate than patients with a regular follow-up at the renal clinic.      
  
Other independent predictors of quality of life:  
− Age: older age being associated with a relatively poor quality of life may be 
related to the presence of significant comorbities.   
− Gender: Evidence has shown that female patients have a poorer quality of life 
than their counterpart male patients. 
− Race: Different studies have demonstrated that African- American patients on 
chronic haemodialysis have a better quality of life than non-African-American 
patients (Mark et al, 2004).         
−  Education: higher education level has been found to be associated with a 
better quality of life. This may be explained by a better understanding of the 
disease and consequently better compliance. 
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− Dialysis adequacy: Increased dialysis dose has been associated with a better 
quality of life (Benz et al, 2000). In another study, increased dialysis dose was 
found to be associated with a decrease number of awakenings at night (Benz et 
al, 2000). 
− Nutritional status: Evidence has shown a correlation between nutrition and 
quality of life even after controlling for comorbidities and dose of 
haemodialysis, hence providing an additional reason for maximising patients’ 
nutritional status and health (Dwyer et al, 2002). 
− Dialysis dose: Evidence has shown either a correlation between dialysis dose 
and quality of life or a lack of correlation between two elements (Manns et al, 
2002; Morton et al, 1996). 
− Dialysis modality: Some studies have shown that quality of life depends upon 
dialysis modality (Merkus et al, 1999).  
− Others: Psychosocial factors, vascular access, duration of haemodialysis, 
number of hospitalisations, primary renal diseases, comorbities.  
Assessing the quality of life for patients with end stage renal disease treated by 
haemodialysis has been considered an important aspect of therapy. Many quality of life 
measures have been used in dialysis patients. Among them are the following:   
• Medical Outcomes Study Short Form 36 (SF-36). 
• Sickness Impact Profile (SIP). 
• Index of Well Being, Index of Overall Life Satisfaction. 
• Index of Psychological Affect. 
• General Health Questionnaire. 
• Simmons Self Esteem Scale. 
• Profile of Mood States. 
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• Multidimensional Health Locus of Control. 
• Modality Specific Stresses Scale. 
• General Treatment Stress Scale. 
• Global Illness Stress on Self and Others, Global Adjustment to Illness Scale. 
• Quality of Life (QL 100 mm) Analogue Scale. 
• Dialysis Relationship Quality Scale. 
• Social Leisure Activities Index, Social Support Satisfaction Scale. 
• General Well-Being Index. 
• Index of General Affect, Overall Life Satisfaction. 
• Katz Activities of Daily Living. 
• Time Trade-off Measures. 
 
Unfortunately, many of these instruments do not have enough evidence for reliability 
and validity. A popular generic measure is the Short Form 36 (SF36), which is a 
health survey, well-validated self- report questionnaire that assesses quality of life of 
patients on maintenance haemodialysis (Kalantar-Zadeh et al, 2001) 
 
It may be difficult however, to compare results from different population cultures in 
view of how different people interpret and rate their quality of life. Nevertheless, the 
score of the SF36 has been used in different studies showing statistically significant 
correlations between serum albumin, haemoglobin and quality of life and subsequent 
correlation with morbidity and mortality with the above two parameters.  
 
The study will help us to identify the parameters of dialysis adequacy and possible 
association in view of laboratory markers of haemoglobin, albumin and the quality of 
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life. Moreover the association between dialysis dose and other outcomes such as blood 
pressure control, sepsis and mortality will be considered. 
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CHAPTER 2. MATERIALS AND METHODS 
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2.1. ETHICS 
 
Human ethics clearance for the study was obtained from the Medical Ethics Committee of 
the University of the Witwatersrand: clearance certificate number M040325. 
 
2.2. CONSENT 
 
Voluntary consent was obtained from patients willing to participate in the study. The 
consent form is attached as Appendix 2. 
 
2.3. STUDY POPULATION 
 
A retrospective review of 61 patients who were on chronic haemodialysis at Johannesburg 
Hospital during January-December 2003 was performed. 
 
2.3.1. The inclusion criteria:  
Patient on maintenance haemodialysis for at least three months; these were outpatients 
receiving haemodialysis three times per week, for an average of four hours for each 
session.  
 
2.3.2. The exclusion criteria:  
Patients on temporary haemodialysis i.e. on holiday haemodialysis as well as patients who 
required bridging haemodialysis for continuous ambulatory peritoneal dialysis related 
complications. 
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2.4. METHODS 
 
2.4.1 The following information was obtained from the patients' records: 
− Demographic data: Age, gender, race 
− Aetiology of chronic kidney diseases 
− Duration of haemodialysis 
− Vascular access 
− Comorbid conditions: Body mass index, viral hepatitis B & C, HIV infection, diabetes 
mellitus. The body mass index (BMI) was calculated as the ratio of weight to height 
squared; the dry weight was used to calculate the BMI of patients on maintenance 
haemodialysis. The measurements of the weight and height were performed using 
"Detecto-scale (Brooklyn. N.Y—USA)". 
  
2.4.2 A smoking history was obtained and accordingly three groups of patients were 
established: 
2.4.2.1 Current smoker 
2.4.2.2 Former smoker 
2.4.2.3 Never smoked (= non smoker) 
  
2.4.3 The records of monthly blood results, which were analysed by the National Health 
Laboratory Service (NHLS), were also reviewed for: 
2.4.3.1 Laboratory values of: 
− Haemoglobin  
− Serum albumin 
− Serum cholesterol 
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− Parathyroid hormone 
2.4.3.2 Parameters of haemodialysis adequacy: 
− Calculated Kt/V 
− Urea reduction ratio (URR) 
− Normalised protein catabolic rate (nPCR) 
These were calculated according to the following formulae: 
 
Where:  
UF: Is the ultrafiltration volume in litres  
W: Is the post dialysis weight in kg 
R: Is the ratio of the post dialysis to predialysis BUN 
 
 
 
 
Where: 
ID (Interdialytic rise in BUN) = Predialysis BUN minus immediate post dialysis BUN 
from the preceding dialysis in mmol/l. 
 
For these calculations, a calculator EL-531VH (SHARP Corporation) also capable of 
performing natural logarithms was used. Furthermore, for weight measurement a Detecto-
scale (Brooklyn N.Y –USA) was used. 
100
BUNsPredialysi
BUNsPredialysiBUNsPredialysi
×
−
=RRU
(g/kg/day)(hours)intervalID
24)BUNinriseID(0.0360.22nPCR ××+=
W)](UF3.5R)[(40.03)ln(RKt/V ÷×−+−−=
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2.4.4 The prospective aspects of this study included: 
 
2.4.4.1 A quality of life questionnaire assessment, using the short form health 
survey with 36 questions (SF36) which is a well documented scoring system that 
has been used and validated as a QOL (Quality Of Life) tool for the general 
population as well as the patients on maintenance haemodialysis, was submitted to 
every patient and a self-assessment of quality of life was then measured by the SF-
36. For patients who could not read or write English, the questionnaire was 
administered by myself with the assistance of an interpreter. 
 
The SF-36 encompasses eight scales (annexed SF-36 questionnaire):  
1. Physical functioning (10 items) 
2. Role physical (4 items) 
3. Bodily pain (2 items) 
4. General health (5 items) 
5. Vitality (4 items) 
6. Social functioning (2 items) 
7. Role emotional (3 items) 
8. Mental health (5 items) 
 
The above 8 scales are divided into two dimensions (physical and mental):   
− The physical component aggregates items from the physical functioning, role physical, 
bodily pain, general health, vitality, and social functioning. 
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− The mental component aggregates items from role-emotional, mental health, and also 
includes elements of general health, vitality, and social functioning. 
 
− The scales vitality and general health are part of both dimensions. Hence every 
dimension includes three specific and two overlapping scales. 
 
In SF36 scoring system, the scales are assessed quantitatively, each on the basis of 
answers to two to ten multiple choice questions, and a score between 0 and 100 is then 
calculated on the basis of well-defined guidelines, with a higher score indicating a better 
state of health 
The scores of the SF-36 dimensions range from 0 to 100, higher scores representing better 
quality of life. 
 
2.4.4.2 Each patient underwent echocardiography performed by the Cardiology Unit using 
SEQUOIA C256 (SIEMENS) echocardiograph machine. 
The following parameters were recorded for every patient:  
− Left ventricle hypertrophy (LVH): Concentric or eccentric 
− Left ventricle dilatation 
− Ejection fraction (EF) 
− Left ventricle diastolic dysfunction 
− Pulmonary pressures 
− Others: wall motion abnormalities; valvular heart disease 
 
2.4.5 Statistical analysis: 
Statistical analyses were performed as follows: 
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• Descriptive statistics, which included percentages and graphical presentation of the 
data. 
• Correlation of dialysis dose (Kt/V) and laboratory markers such as haemoglobin 
(Hb) and serum albumin. The short-form 36 (SF-36) scoring results were also 
correlated with Kt/V.  
• Statistical inference including: 
- Mean confidence intervals of indicators of dialysis adequacy of adult 
patients on chronic haemodialysis at Johannesburg hospital in 2003. This 
involved Kt/V, Urea Reduction Rate (URR) and normalised Protein 
Catabolic Rate (nPCR).   
- Chi-square tests of association between hypertension and diastolic 
dysfunction and also between aetiology of ESRD and LVH.  
- Two-sample t-tests were performed to study the relationship between:  
i) LVH and duration of haemodialysis, aetiology of ESRD, Hb status.   
ii) Diastolic dysfunction and anaemia, duration of haemodialysis 
iii) Valvular heart disease and serum PTH, Ca x P product, serum PO4 , 
serum Calcium, duration of haemodialysis. 
iv) Influence of Kt/V on BP control, hospitalisation and sepsis. 
Conclusions were made at 95% confidence levels. That is, differences and relationships 
were considered statistically significant when the probability value, p, was less than 0.05 
(p<0.05).  
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CHAPTER 3. RESULTS 
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3.1. DEMOGRAPHIC DATA 
 
At the initiation of the study, 61 patients were enrolled. During the course of the study, 
four patients passed away and three patients were transplanted. All these events happened 
at different periods of time. Therefore, they were obviously ruled out for some of the study 
parameters. Furthermore, only patients who have been on maintenance haemodialysis for 
at least three months duration were considered for the study.  
 
3.1.1. GENDER  
 
Figure 3 GRAPH SHOWING THE GENDER OF ADULT PATIENTS ON 
CHRONIC HAEMODIALYSIS AT JOHANNESBURG HOSPITAL IN 2003. 
 
 
52% of adult patients on chronic haemodialysis at Johannesburg Hospital during 2003 
were male and 48% were female. 
n=61
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3.1.2. PATIENT POPULATION RACE GROUP 
 
Figure 4 GRAPH SHOWING THE ADULT PATIENT POPULATION ON 
CHRONIC HAEMODIALYSIS AT JOHANNESBURG HOSPITAL IN 2003. 
 
 
 
The majority of patients on chronic haemodialysis at Johannesburg Hospital in 2003 were 
black Africans (67%), the rest being 20% Caucasian, 8% coloured and 5% Indian. 
n = 61
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3.1.3. AGE 
 
Figure 5 HISTOGRAM OF PATIENTS' AGES (IN YEARS) ON CHRONIC 
HAEMODIALYSIS AT JOHANNESBURG HOSPITAL IN 2003. 
 
 
Most of the adult patients on chronic haemodialysis at Johannesburg Hospital in 2003 were 
between the age group 20-50 years, the biggest group belonging to the age group 40 to 50 
year old. Only two patients were more than 60 years old and none were less than 20 years. 
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3.2. DURATION OF HAEMODIALYSIS (IN YEARS)  
 
Figure 6 HISTOGRAM SHOWING THE DURATION OF HAEMODIALYSIS (IN 
YEARS) OF ADULT PATIENTS AT THE RENAL UNIT AT JOHANNESBURG 
HOSPITAL IN 2003. 
  
 
The duration of haemodialysis of most of the patients was between less than one year to 10 
years; only one patient was on chronic haemodialysis for more than 20 years. 
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3.3. PRIMARY RENAL DISEASE  
 
Table 2 PRIMARY RENAL DISEASE RESULTING IN END STAGE RENAL 
FAILURE (ESRF) IN ADULT PATIENTS (n= 61) ON CHRONIC 
HAEMODIALYSIS AT JOHANNESBURG HOSPITAL IN 2003.  
 
AETIOLOGY NUMBER OF PATIENTS  PERCENTAGE  
Hypertension 26 42.62% 
Glomerulonephritis 11 18.03% 
Polycystic kidney disease 1 1.64% 
Diabetes 4 6.56% 
Reflux 5 8.20% 
Congenital kidney disease 3 4.92% 
Trauma-surgery 2 3.28% 
Unknown 9 14.75% 
 
 
Hypertension remains the most common presumed cause of ESRF, followed by 
glomerulonephritis. A significant number of patients have ESRF of unknown aetiology. Of 
note, diabetes was in the 5th position of primary renal disease; this is related to selection-
bias, as only those patients deemed suitable for renal transplantation were offered chronic 
dialysis. 
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3.4. COMORBIDITIES 
3.4.1. SMOKING STATUS 
 
Figure 7 GRAPH SHOWING THE SMOKING STATUS OF ADULT PATIENTS 
ON CHRONIC HAEMODIALYSIS AT JOHANNESBURG HOSPITAL IN 2003. 
 
 
74% of patients (n=45) never smoked, 15% (n=9) were current smokers and 11% (n=7) 
were former smokers. Among the smokers 89% were male and 11% were female. In 
addition, the smokers were all in the age group between 25-50 years. They were all 
moderate smokers (1 to 5 per day), trying hard to quit smoking. 
 
 
 
n=61
74%
11%
15%
Never Smoked
Current Smoker
Former Smoker
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3.4.2. SERUM PTH LEVEL 
 
Table 3 SERUM PTH LEVELS OF ADULT PATIENTS (n=58) ON CHRONIC 
HAEMODIALYSIS AT JOHANNESBURG HOSPITAL IN 2003.  3 PATIENTS’ 
DATA ON SERUM PTH LEVELS WERE NOT FOUND DURING THE STUDY. 
 
SERUM PTH (pg/ml) NUMBER OF PATIENTS PERCENTAGE 
<150 17 29% 
150-300 7 12% 
300-1000 26 45% 
≥1000 8 14% 
 
According to K/DOQI guidelines which recommends a serum PTH level between  
150-300 pg/ml, 59% (n=34) of patients had hyperparathyroidism  
(PTH level ≥300pg/mL), 14% having PTH levels of more than 1000 pg/ml.  
It is the intact serum PTH that was measured during our study.  
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3.4.3. BMI 
 
Table 4 BMI (kg/m2 ) OF ADULT PATIENTS ON CHRONIC HAEMODIALYSIS 
AT JOHANNESBURG HOSPITAL IN 2003 
 
BMI 
(kg/m2) 
NUMBER OF PATIENTS PERCENTAGE 
<18.5 4 6.6% 
18.5-24.9 40 65.6% 
25.0-29.9 12 19.7% 
30.0-34.9 2 3.3% 
35.0-39.9 2 3.3% 
≥40 1 1.6% 
 
65.6% (n=40) of patients had a normal BMI, 19.7% (n=12) were overweight (pre-obese) 
and the rest of the patients were obese with 1.6% (n=1) having morbid obesity. 
 
World Health Organisation classification of overweight and obesity based on BMI: 
Underweight: <18.5 kg/m2                                        Normal weight: 18.5-24.9 kg/m2 
Pre-obese (overweight): 25.0 - 29.9 kg/m2               Obese Class I: 30.0-34.9 kg/m2 
Obese Class II: 35.0-39.9 kg/m2  
Obese Class III (morbid obesity): ≥40.0 kg/m2 
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3.4.4. HEPATITIS B&C AND HIV INFECTION 
 
Figure 8 GRAPH SHOWING HEPATITIS B & C AND HIV INFECTION STATUS 
OF ADULT PATIENTS ON CHRONIC HAEMODIALYSIS 
 
 
3% (n=2) of patients were HCV positive, 5% (n=3) were HBV positive, 3% (n=2) were 
HIV positive, and 2% (n=1) had co-infection Hepatitis C & HIV.    
n = 6 1
5 %
8 7 %
3 %
3 % 2 %
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3.4.5. ECHOCARDIOGRAPHIC FINDINGS IN ADULT PATIENTS (n=59) 
ON CHRONIC HAEMODIALYSIS AT JHB HOSPITAL IN 2003 
 
Two patients had already died and their echocardiographic data were not available. 
3.4.5.1. Left Ventricular configuration 
 Table 5 LEFT VENTRICULAR CONFIGURATION 
LV CONFIGURATION NUMBER OF PATIENTS PERCENTAGE 
Concentric 40 68% Hypertrophy 
Eccentric 4 7% 
Dilated 6 10% 
Normal 9 15% 
 
75% (n=44) of patients had LVH, with 68% (n=40) having concentric LVH; 10% (n=6) 
had dilated LV.   The mean EF was 63.16%; range 29.63% to 87.77%. 
 
The statistical analysis of the association between LV configuration and the parameters of 
haemodialysis duration, aetiology of ESRD and haemoglobin shows the following:  
• Using Fisher's- exact test (Chi-squared test), there is an association between LVH 
and hypertension; p<0.05. 
• Using T-test the effect of haemoglobin on LVH is not statistically significant 
(p=0.4307). Similarly, there is no effect of haemodialysis duration on LVH 
(p=0.9788). 
• The analysis for dilated LV and the above parameters was not performed due to the 
sample size, which is very small. 
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3.4.5.2. Left Ventricular function 
 
Table 6 LEFT VENTRICULAR FUNCTION 
  
LV FUNCTION NUMBER OF PATIENTS PERCENTAGE 
Diastolic dysfunction 35 59% 
Systolic dysfunction 3 5% 
Systolic & Diastolic dysfunction 4 7% 
Normal 17 29% 
 
59% (n=35) of patients had diastolic dysfunction, 5% (n=3) had systolic dysfunction, 
whereas 7% (n=4) had mixed systolic and diastolic dysfunction.  
The statistical analysis association between LV function and the parameters of 
hypertension, haemoglobin, duration of haemodialysis duration shows the following:  
• Using Fisher's- exact test (Chi-squared test), there is a statistically significant 
association between hypertension and diastolic dysfunction; p<0.05. 
• Using the T-test there is no effect of haemodialysis duration and serum haemoglobin 
levels on the diastolic dysfunction. 
• Since the sample size for systolic dysfunction was very small (n = 3), no formal 
statistical inference was performed. The same observation applies to the analysis 
concerning the effect of Hb and haemodialysis duration on combined systolic and 
diastolic dysfunction (n = 4).  
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3.4.5.3. VALVULAR HEART DISEASE 
 
Figure 9 VALVULAR HEART DISEASE 
 
 
7% (n=4) had tricuspid regurgitation (TR), 7% (n=4) had mixed mitral valve disease, 5% 
(n=3) had mitral regurgitation, 3% (n=2) had aortic regurgitation, and the same number 
(n=2) with mixed tricuspid valve disease. One patient each had aortic stenosis, mitral 
stenosis and mixed aortic valvular disease.  
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The statistical analysis of the association between valvular heart disease and duration of 
haemodialysis, Ca x P product and plasma PTH shows the following:  
• Using T-test, there is a statistically significant effect of haemodialysis duration on 
valvular heart disease (p=0.0182). Using the T-test there was no effect of Ca x P 
product on valvular heart disease (p=0.8116). The same applies (p>0.05) for the 
following: plasma PTH , serum PO4, serum calcium. 
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3.4.5.4. Pulmonary hypertension 
Figure 10 PULMONARY HYPERTENSION 
 
24% (n=14) had pulmonary hypertension, with pulmonary artery pressures ranging from 
35 to118mmHg; 76% (n=45) had normal pulmonary pressure. 
 
Pulmonary hypertension was defined as pulmonary artery systolic pressure of more than 
35mmHg and was determined by two-dimensional doppler echocardiography imaging.  
24%
76%
Pulmonary hypertension(PAP>=35mmHg)
Normal(PAP<35mmHg)
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3.4.6. LIPID STATUS OF ADULT PATIENTS (n=53) ON CHRONIC 
HAEMODIALYSIS AT JOHANNESBURG HOSPITAL IN 2003.  
 
8 patients' data for serum lipids were not available.  
3.4.6.1. DYSLIPIDAEMIA 
 
Figure 11 GRAPH SHOWING PATIENTS WITH DYSLIPIDAEMIA 
  
 
62% (n=33) had dyslipidaemia, whereas 38% (n=20) had normal lipograms.  
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61
3.4.6.2. LIPID PROFILES OF PATIENTS WITH DYSLIPIDAEMIA 
 
Table 7 LIPID PROFILES OF PATIENTS WITH DYSLIPIDAEMIA 
 
LIPID PROFILES NUMBER OF PATIENTS PERCENTAGE 
Triglycerides (>1.5 mmol/l) 10 19% 
LDL - Cholesterol (>3 mmol/l) 7 13% 
HDL - Cholesterol (<1.2 mmol/l) 27 51% 
Total - Cholesterol (>5 mmol/l) 3 6% 
 
Most of the patients had low HDL-cholesterol (51%), with mean 1.13mmol/l and range 0.5 
to 2.4mmol/l and hypertriglyceridaemia (19%) with mean 1.28mmol/l and range 0.5 to 
4.9mmol/l. A significant number of patients had high LDL cholesterol (13%) with mean 
2.12mmol/l and range 0.8 to 4.5mmol/l  
 
Normal ranges for Total cholesterol:    ≤ 5.0 mmol/l 
                                  Triglycerides:         ≤ 1.5 mmol/l 
                                  HDL-Cholesterol:  ≥ 1.2 mmol/l 
                                  LDL- Cholesterol: ≤ 3.0 mmol/l   
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3.5. VASCULAR ACCESS 
 
Figure 12 GRAPH SHOWING VASCULAR ACCESS OF ADULT PATIENTS ON 
CHRONIC HAEMODIALYSIS AT JOHANNESBURG HOSPITAL IN 2003. 
 
 
 
Although 61% (n=37) of patients on chronic haemodialysis at Johannesburg Hospital in 
2003 have a permanent access (A-V fistula/graft), a significant number of patients (39%, 
n=24) were still being dialysed with temporary catheters. 
n=61
39%
61%
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TEMPORARY CATHETERS
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3.6. INDICATORS OF DIALYSIS ADEQUACY OF ADULT 
PATIENTS (n=58) ON CHRONIC HAEMODIALYSIS AT 
JOHANNESBURG HOSPITAL IN 2003. 
 
3 patients' data on indicators of dialysis adequacy were not available. 
 
Table 8 INDICATORS OF DIALYSIS ADEQUACY OF ADULT PATIENTS (n=58) 
ON CHRONIC HAEMODIALYSIS AT JOHANNESBURG HOSPITAL IN 2003. 
 
 
Kt/V  
(1.34 ± 0.25) 
URR  
(68.82 ± 9.19)% 
nPCR  
( 0.82±0.20) 
g/kg/day 
≥1.2 <1.2 ≥1.3 <1.3 ≥65% <65% ≥70% <70% ≥0.8 <0.8 
74% 
(n=43) 
26% 
(n=15) 
60% 
(n=35) 
40% 
(n=23) 
74% 
(n=43) 
26% 
(n=15) 
55% 
(n=32) 
45% 
(n=26) 
50% 
(n=29) 
50% 
(n=29) 
 
An acceptable number of patients were adequately dialysed: 
• 74% of patients (n = 43) had Kt/V ≥1.2  
• 60% of patients (n = 35) had Kt/V ≥1.3  
• 74% of patients (n=43) had URR ≥ 65% 
• 55% of patients (n = 32) had URR ≥70%  
• 50% of patients (n = 29) had nPCR ≥0.8 g/kg/day  
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Parameters considered for dialysis adequacy: 
1. Kt/V (Urea Kinetic Modelling ) DOQI: ≥1.3 
2. URR (Urea Reduction Ratio) DOQI: ≥70% 
3. nPCR (Normalised Protein Catabolic Rate ) in gram/kg/day (NCDS: ≥0.8). 
These parameters, plus signs and symptoms are important indicators for dialysis adequacy 
and they should be checked monthly (haemodialysis work group recommendation).     
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3.7. INDICATORS OF DELIVERED DIALYSIS DOSE (Kt/V) 
AND PATIENT OUTCOMES IN 2003. 
 
3.7.1. Correlation between Kt/V and Haemoglobin (Mean Hb: 
9.43±1.51) g/dl 
 
Figure 13 CORRELATION BETWEEN Kt/V AND HAEMOGLOBIN 
 
 
 The correlation between dialysis dose (Kt/V) and Hb is statistically significant (p<0.05).  
Correlation between Kt/V and Haemoglobin
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3.7.2. Correlation between Kt/V and Albumin (Mean Albumin: 
38.75±4.06) g/l 
Figure 14 CORRELATION BETWEEN Kt/V AND ALBUMIN 
 
The correlation between dialysis dose (Kt/V) and Albumin was not statistically significant 
at the 95% confidence level.  
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3.7.3. Correlation between Kt/V and health related quality of life using 
questionnaire SF-36.  
 
During this prospective component of the study, three patients had already passed away 
and 3 others patients had received kidney transplants, and therefore they did not 
participate in the study. 
The SF-36 questions, health related quality of life questions are grouped into eight scales: 
physical functioning (10 items), role physical (4 items), bodily pain (2 items), general 
health (5 items), vitality (4 items), social functioning (2 items), role emotional (3 items) 
and mental health (5 items). See Appendix 4&5.  
Figure 15 CORRELATION BETWEEN Kt/V AND SF-36 
 
There is a statistically significant correlation (p<0.05) between dialysis dose (Kt/V) and 
SF-36. 
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3.7.4. Correlation between Kt/V and Physical Health 
 
Physical health is one of the two dimensions with the mental health of the SF-36 and 
consists of five scales: physical functioning (10-question scale), role physical (4-item 
scale), bodily pain (2-item scale), vitality (4-item scale), and general health (5-item scale). 
(See Appendix 4&5)  
 
Figure 16 CORRELATION BETWEEN Kt/V AND PHYSICAL HEALTH 
 
The correlation between dialysis dose (Kt/V) and physical health is statistically significant 
(p<0.05). 
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3.7.5. Correlation between Kt/V and Mental Health 
 
Mental health is one of the two dimensions of SF-36 together with physical health and it 
aggregates role-emotional (2 -item scale), mental-health (5 -item scale), general health (5- 
item scale), vitality (4- item scale), and social functioning (2- item scale).   
 
Figure 17 CORRELATION BETWEEN Kt/V AND MENTAL HEALTH 
 
 
The correlation between the dialysis dose (Kt/V) and mental health was not statistically 
significant (p=0.5208). 
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3.7.6. Correlation between Kt/V and Physical Functioning 
 
Physical functioning is one of the 5 scales of physical health; it is a 10-question scale that 
captures the ability to deal with the physical requirements of life, such as attending to 
personal needs, walking and flexibility. (See appendix 4&5).  
 
Figure 18 CORRELATION BETWEEN Kt/V AND PHYSICAL FUNCTIONING 
 
There is a statistically significant correlation between dialysis dose (Kt/V) and physical 
functioning (p<0.05).  
Correlation between Kt/V and Physical Functioning
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3.7.7. Correlation between Kt/V and Role Physical  
 
Role physical is one of the 5 scales of the physical health dimension; it is a 4-item scale 
that evaluates the extent to which physical capabilities limit activity.(See appendix 4 &5).  
 
Figure 19 CORRELATION BETWEEN Kt/V AND ROLE PHYSICAL 
 
The correlation between dialysis dose (Kt/V) and role physical is statistically significant 
(p=0.007).  
 
Graph 7: Correlation between Kt/V and Role Physical
(r=0.35958; **p=0.007;  N=55)
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3.7.8. Correlation between Kt/V and Bodily Pain 
 
Bodily pain is one the 5 scales of physical health and it is a 2-item scale that evaluates the 
perceived amount of pain experienced during the previous four weeks and the extent to 
which that pain interfered with normal work activities. (See Appendix 4&5)  
 
Figure 20 CORRELATION BETWEEN Kt/V AND BODILY PAIN 
 
 
The correlation between the dialysis dose (Kt/V) and bodily pain is not statistically 
significant (p=0.0885). 
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3.7.9. Correlation between Kt/V and General Health 
 
General health is one of the two overlapping components of both physical health and 
mental health dimensions; it is a 5-item scale that evaluates general health in terms of 
personal perception. (See Appendix 4&5). 
 
Figure 21 CORRELATION BETWEEN Kt/V AND GENERAL HEALTH 
 
There is no correlation between dialysis dose (Kt/V) and general health (p=0.1053). 
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3.7.10. Correlation between Kt/V and Vitality 
 
Vitality is one of the overlapping scales of both general health and physical health; it 
consists of a 4-item scale that evaluates feelings of pep, energy and fatigue. (See Appendix 
4&5).  
 
Figure 22 CORRELATION BETWEEN Kt/V AND VITALITY 
 
 
There is no correlation between dialysis dose (Kt/V) and vitality (p=0.2145). 
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3.7.11. Correlation between Kt/V and Social Functioning 
 
Social functioning is a 2-item scale that evaluates the extent and amount of time, if any, 
that physical health or emotional progress interfered with family, friends, and social 
interactions during the previous 4 weeks. (See Appendix 4&5). 
 
Figure 23 CORRELATION BETWEEN Kt/V AND SOCIAL FUNCTIONING 
 
 
There is no correlation between dialysis dose (Kt/V) and social functioning (p=0.7321). 
 
 
Correlation between Kt/V and Social Functioning
(r=0.04721;  p=0.7321;  N=55)
0
20
40
60
80
100
120
0 0.5 1 1.5 2 2.5
Kt/V
So
ci
al
 
Fu
n
ct
io
n
in
g
  
 
 
76
3.7.12. Correlation between Kt/V and Role Emotional 
 
Role emotional is a 3-item scale that evaluates the extent, if any, to which emotional 
factors interfere with work or other activities. (See Appendix 4&5). 
 
Figure 24 CORRELATION BETWEEN Kt/V AND ROLE EMOTIONAL 
 
 
There was no correlation between dialysis dose (Kt/V) and role emotional.  
 
Correlation between Kt/V and Role Emotional
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3.7.13. Relationship between delivered dialysis dose (Kt/V) and 
hospitalisation, blood pressure control, sepsis and mortality 
 
3.7.13.1. Kt/V and hospitalisation 
The main causes of hospitalisation were sepsis and vascular access creation; there was no 
statistically significant effect of Kt/V on hospitalisation (p=0.1534; T-test). 
 
3.7.13.2. Kt/V and blood pressure control 
Hypertension is defined as predialysis blood pressure ≥ 140/90 (MAP>106 mmHg) when 
the patient is believed to be at so-called “dry weight”. The effect of Kt/V on pre- 
haemodialysis blood pressure control was not statistically significant (p=0.4819; T-test). 
  
3.7.13.3. Kt/V and sepsis 
In 2003, there were in total 25 cases of sepsis and more than 90% were catheter-related 
sepsis; there was a statistically significant effect of Kt/V on sepsis (p<0.05; T-test). In fact 
the mean Kt/V for patients with sepsis was 1.1809 and mean Kt/V of patients without 
sepsis was 1.3763.   
3.7.13.4. Kt/V and mortality 
4 patients on chronic haemodialysis died during 2003. The statistical analysis of the 
association between Kt/V cannot be performed due to the sample size, which is very small. 
However, 50% of deaths were caused by vascular access problems and 50% of deaths were 
caused by sepsis. Overall, all the patients who died were underdialysed, with Kt/V of less 
than 1.2. 
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CHAPTER 4. DISCUSSION 
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4.1. Demographic data and primary renal disease 
 
A total of 61 patients attending chronic haemodialysis at Johannesburg General Hospital in 
2003 were included in the study. This number excludes patients on bridging haemodialysis 
for continuous ambulatory peritoneal dialysis-related complications as well as patients on 
holiday haemodialysis.    
 
During the study, 4 patients died and 3 patients had received cadaver kidney 
transplantation and were therefore included in the study for only a certain number of 
parameters and they were ruled out especially from the prospective components of the 
study, which are echocardiography and the quality of life assessment using the SF-36 
questionnaire. In addition, a certain number of data of the patients' results could not be 
found.  
 
The number of male patients was slightly higher than that of the female patients on 
maintenance haemodialysis (52% versus 48%). The mean age of the patients was  
40.02 ± 10.79 years. This age of the patients on chronic haemodialysis is different from 
that of Europe (60.2±15.2 years), Japan (58.6±12.5 years) and USA (60.5±15.5 years) 
(Goodkin et al, 2004); as only those patients who were eligible for kidney transplantation 
were offered chronic dialysis. The gender difference was also observed in favour of male 
preponderance: the European haemodialysis population was 58% male versus 62% in 
Japan and 53% in the United States (Goodkin et al, 2004). 
 
Concerning the age difference between our chronic haemodialysis patients in 2003 at 
Johannesburg Hospital, it is most likely related to stringent selection criteria for our 
chronic dialysis program, which does not apply in developed countries where the financial 
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resources are not as limited as in South Africa or in other underdeveloped or developing 
nations.    
 
 As should be expected in South Africa, the majority of patients on maintenance 
haemodialysis were black-Africans. This is a reflection of several factors: 
− The fact that in South Africa, black- Africans constitute the majority of the 
population: they constitute about 73% of the South African population. 
− Hypertension, which is the leading cause of end stage renal disease in the South 
African black population (Veriava and Milne, 2002) was also the most common 
cause of ESRD in our study population. This is also the reflection of the statistics 
derived from the South African Dialysis and Transplantation Registry (SADTR), 
which stipulates that hypertensive renal disease is clearly the most important cause of 
ESRD in black South Africans, and malignant as well as non-malignant hypertension 
is responsible for ESRD (see Table 9). It also reports that the three leading causes of 
ESRD in South Africans are hypertension, glomerulonephritis and unknown 
aetiology. This is similar to the USA, where hypertension was found to be the most 
common cause of ESRD in the African-American population (Grundy et al, 1999), 
contributing to 29% of patients with ESRF and is secondary to diabetes mellitus. 
Overall in the USA and Europe, diabetes was the most common cause of ESRD of 
patients on MHD, followed by hypertension and glomerulonephritis (Grundy et al, 
1999). 
The number of patients on MHD with diabetes mellitus as the primary cause of renal 
disease in our study population was relatively small (7%). This is because of 
stringent selection criteria for renal replacement therapy and the frequently 
associated co-morbidities of patients with diabetes mellitus when they reach the stage 
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for renal replacement therapy such as congestive cardiac failure, ischaemic heart 
disease, peripheral vascular disease with subsequent vascular access problems, 
cerebro-vascular diseases such as strokes, and others such as dysautonomia, etc. 
This study found a significant number of patients on maintenance haemodialysis with 
ESRD of unknown aetiology (15%). This figure is different from the South African 
Dialysis and Transplant Registry report (SADTR) of 1998 on the causes of chronic 
renal failure, which showed that 19.5% of patients with ESRD were of uncertain 
aetiology. 
 
Table 9 Report of causes of ESRD (SADTR, 1998) 
 
Aetiology Percentage 
CRF - Uncertain aetiology   19.5 
Glomerulonephritis    23.2 
Pyelonephritis     8.0 
Drug induced CRF   5.7 
Cystic disease     5.5 
Hereditary/congenital    1.7 
Vascular (includes hypertension)  20.7 
Systemic disease    11.8 
Other/miscellaneous    4.1 
 
 
4.2. Dialysis adequacy 
 
Concerning parameters of dialysis adequacy, it was found that most of the patients 
were reasonably well dialysed, although a significant number of patients on 
maintenance haemodialysis were underdialysed according to the parameters of 
dialysis adequacy. See Table 8 on indicator of dialysis adequacy of adult patients on 
  
 
 
82
chronic haemodialysis at Johannesburg Hospital in 2003. In fact, 74% of our study 
patients on chronic haemodialysis had a Kt/V ≥ 1.2 and 60% had a Kt/V ≥ 1.3. The 
K/DOQI recommendation (Rajiv et al, 2004) is a Kt/V ≥ 1.3. 
 
Some of the following factors plus a number of comorbid conditions may explain the 
cases of dialysis inadequacy, which were observed:  
 
1. Vascular access problems: 
The status of vascular access of the patients on chronic haemodialysis in year 2003 
were as follow:      
• 61% permanent access (A-V Fistula and Graft) 
• 39% temporary catheters.  
The problem of vascular access is more likely the result of the fact that most of the 
patients elected for haemodialysis did not have permanent vascular access at the 
initiation of haemodialysis. On the contrary, K/DOQI clinical practice guidelines 
(Rayner et al, 2004) for vascular access sets goals of primary AV fistulae being 
constructed in at least 50% of all new kidney failure patients electing to receive 
haemodialysis as their initial form of renal replacement therapy and 40% of 
prevalent haemodialysis patients with a native AV fistula and only less than 10% of 
chronic maintenance haemodialysis patients being maintained on catheters as their 
permanent haemodialysis access. In this context, chronic catheter access is defined 
as the use of a dialysis catheter for more than 3 months in the absence of a maturing 
permanent access. Furthermore, the study of Rayner et al in the Dialysis Outcomes 
and Practice Patterns Study (DOPPS) has shown that performance against these 
guidelines varies widely among countries. Japan, Italy, Germany Spain, and France 
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average more than 75% of their patients dialysing through AV fistulae. In the USA, 
however, the ratio is 30% fistulae to 42% grafts and around 10% or less of their 
patients using temporary catheters. The lack of vascular surgery and theatre time 
has been responsible for inadequate vascular access creation. This is very crucial in 
view of the K/DOQI vascular access guideline, which recommends referral for 
vascular access surgery within 1 month of commencing dialysis or when creatinine 
clearance is less than 25ml/min (Rayner et al, 2004). 
 
2. Poor compliance: For different reasons, not every patient attended all dialysis 
sessions as recommended (three sessions per week for four hours each): lack of 
transport and social problems were the culprits for non-compliance. 
 
3. Lower than prescribed time of dialysis especially for complications related to 
haemodialysis i.e. cramps, symptomatic hypotension, vascular problems during 
haemodialysis etc. 
 
4. Type of dialysis membranes: There were no high flux membranes in the chronic 
haemodialysis unit in 2003. Although the HEMO Study (Rajiv et al, 2004) 
showed that neither more dialysis nor high-flux filters reduced hospitalisation or 
deaths among trial participants as a whole, findings for certain groups of patients 
are intriguing. In fact, the higher dialysis dose appeared to reduce the risk of death 
and hospitalisation among women and the high- flux filter appeared to reduce the 
risk of death among patients who had been on haemodialysis for longer than 3,5 
years when they entered the study; further study is needed before conclusions can 
be drawn (Rajiv et al, 2004). Similarly to the HEMO study, the first major 
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National Institute of Health clinical trial for dialysis in more than 20 years, 
confirms that the minimum dose recommended by treatment guidelines is 
adequate and that, in general, a higher dose and special filters provide no added 
benefit to patients. 
At this point in time, one is awaiting the conclusions of the membrane 
permeability outcome study, which is a randomised controlled clinical trial in 
progress at 9 clinical centres in Europe that has been designed to prospectively 
evaluate the long-term effect of membrane permeability (i.e. flux) on clinical 
outcomes such as mortality, morbidity, vascular access survival, and nutritional 
status. 
 
 
5. Other important markers of haemodialysis adequacy including associated 
comorbidities: 
           
          5.1 Anaemia 
The mean haemoglobin (Hb) was found to be 9.43±1.51 g/dl in our patients on 
chronic haemodialysis. This value is lower than the recommended DOQI guideline, 
which recommends a Hb of 11g/l to 12g/l and the haematocrit of 33% to 36%. The 
mean Hb in our study population was lower, compared to other countries: Mean Hb 
levels were 12g/dl in Sweden; 11,6 to 11,7g/dl in the United States, Spain, Belgium, 
and Canada; 11,1 to 11,5 g/dl in Australia, New Zealand, Germany, Italy, The United 
Kingdom, and France; and 10,1g/dl in Japan (Pisoni et al, 2004). The factors, which 
are responsible for the low haemoglobin levels in our patients, compared to the 
DOQI guidelines and other countries’ haemoglobin levels, are the following: 
  
 
 
85
- Loss of blood due to gastro-intestinal bleeding is often observed in uraemia; 
multiple venesections, blood sequestered in the extracorporeal circuit.  
 
- The lack of consistent supplies of erythropoietin, which has been a frequent 
problem in the chronic haemodialysis unit, despite many meetings involving the 
nephrology unit, the pharmacy and administration of the hospital in order to 
discuss the problem and to highlight the importance of uninterrupted availability 
of erthropoietin in patients with ESRD on maintenance haemodialysis. 
Erythropoetin in patients on chronic haemodialysis helps to correct the anaemia, 
and consequently decreases the rate of cardiovascular complications, especially 
left ventricular hypertrophy (Ter Arkh, 2004). This issue can partially explain our 
study finding of patients with LVH (75%).  Hypertension is the main risk factor 
for LVH in dialysis patients, followed by age and anaemia (Stewart GA et al, 
2004). Moreover, anaemia is a risk factor for LVH, dilated cardiomyopathy and a 
non-classical risk of ischemic heart disease.  
This is meaningful, in view of our finding that in our study population 21% of 
patients had uncontrolled pre-haemodialysis blood pressure.  
 
− Insufficient dialysis dose: There is good evidence that dialysis adequacy has 
resulted in better control of anaemia and other parameters correlating with 
dialysis adequacy such as hypertension and patients’ nutritional status 
(Panagoutsos and Yannatos, 2002). This was not demonstrated in this study. 
  
− Dialysis membrane: High- flux haemodialysis membranes were not used in the 
chronic haemodialysis unit. Evidence has shown that high-flux dialysis use is 
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effective in controlling renal anaemia and this beneficial effect of high- flux 
dialysis is probably mediated by the improved clearance of moderate and high 
molecular weight toxins (Ayli et al, 2004). 
 
− Hyperparathyroidism: In our study population, according to K/DOQI guidelines, 
59% of patients on chronic haemodialysis had hyperparathyroidism (intact PTH 
≥ 300pg/ml), whereas 29% had hypoparathyroidism (intact PTH ≤ 150pg/ml). 
This study has shown that secondary hyperparathyroidism may contribute to 
inadequate anaemia control, and may result in larger doses of erythropoietin 
being required or resistance to erythropoetin therapy in haemodialysis patients. 
The evidence has shown that there was an inverse correlation between intact PTH 
with haematocrit and haemoglobin levels, and between alkaline phosphatase and 
haemoglobin (Baradaran and Nasri, 2001). It is suggested that PTH, when 
present in excessive amounts, interferes with normal erythropoiesis by down-
regulating erythropoietin receptors on erythroid progenitor cells in the bone 
marrow (Sikole, 2000). Furthermore, besides the involvement of serum PTH in 
anaemia and mineral bone metabolism together with serum phosphorus, calcium, 
and calcium-phosphorus product, it has been found to participate in other 
pathologic processes such as cardiovascular abnormalities: cardiac structural 
diseases, pulmonary hypertension. In fact, adverse effects of secondary 
hyperparathyroidism on LV function and structure in this study supports the role 
of excess PTH in the development of left ventricular (LV) hypertrophy as well as 
low LV ejection fraction in patients with end-stage renal disease on 
haemodialysis. Hence, PTH needs more stringent control, in order to reduce the 
risk of cardiovascular morbidity and mortality in haemodialysis patients 
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(Baradaran and Nasri, 2004). It is most likely that secondary 
hyperparathyroidism, in concert with hypertension and low haemoglobin levels, 
has contributed to the magnitude of LVH observed in our patients on chronic 
haemodialysis. In addition, serum PTH has been proposed to play a role in 
pulmonary hypertension and in cardiovascular disease (Amin  et al, 2003). In our 
study neither Ca x PO4 product nor calcium and phosphorus had an impact on 
valvular heart disease (p>0.05). Although, with echocardiography results there 
was no evidence of rheumatic heart valve disease or elements of infective 
endocarditis as the background, it is important according to Schonenberger  et al  
to rule out the role of chronic inflammation in haemodialysis patients with 
valvular heart disease.  
Concerning cardiovascular comorbidity, the study has demonstrated a high 
prevalence (39.7%) of pulmonary hypertension among patients with ESRD 
receiving long-term haemodialysis with surgical arteriovenous access (Yigla et 
al, 2003). Both ESRD and long-term haemodialysis via arteriovenous access may 
be involved in the pathogenesis of pulmonary hypertension by affecting 
pulmonary vascular resistance and cardiac output (Yigla et al, 2003). Moreover, 
the evidence has shown significant improvement of pulmonary hypertension after 
ligation of brachiocephalic arteriovenous fistulae (Clarks et al, 2002). This may 
explain our finding of 24% of patients on chronic haemodialysis with pulmonary 
hypertension.  This relatively lower prevalence, compared to the above study of 
39,7%, may be secondary to the presence of a significant number of patients on 
chronic haemodialysis without permanent vascular access (39% of patients 
without AV fistulae, receiving haemodialysis with temporary catheters). The 
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study by Unger et al, 2004 has shown that closure of large and/ or symptomatic 
AVF causes long-term regression of LV hypertrophy.  
 
Infection or inflammation: The anaemia in these HD patients is most frequently 
the result of anaemia of chronic disorder as well as erythropoietin deficiency. In 
fact studies have proven that these conditions are associated with higher 
concentrations of proinflamatory cytokines and higher levels of erythropoietin 
hyporesponsiveness and poor clinical outcome, including a 4-fold increase in 
mortality, greater hospitalisation rate, and a poor quality of life in maintenance 
haemodialysis patients (Kalantar-Zadeh et al, 2004).  
 
− Other possible factors causing anaemia in chronic haemodialysis patients:  
• Iron deficiency, although unlikely in view of the patients’ iron status in our 
study, which is a mean serum ferritin of 567.76±309.93 µg/l, although the 
presence of infection/inflammation has to be excluded.  
• Vitamin deficiency: B12 and Folate, although unlikely to be the cause of 
anaemia as the patients on chronic haemodialysis were all on vitamin therapy: 
B complex, ascorbic acid and Folate.  
 
5.2. Nutritional status  
     5.2.1 Albumin 
The mean plasma albumin level (± SD) for the patients on chronic haemodialysis 
was 38.75±4.06 g/l. This is an acceptable value, comparable with other countries' 
mean plasma albumin levels: USA (36 g/l), France (38.7 g/l), Italy (39.8 g/l), Spain 
(37.2 g/l); (Combe et al, 2004).  
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Serum albumin, which is one of the markers of nutrition, is however non-specific, in 
fact it is a negative acute phase reactant protein and falsely low results can occur in 
relation to infection or inflammation, decreased protein synthesis secondary to liver 
disease or urinary losses (albuminuria), and overhydration. In addition, serum 
albumin is slow to change (the half-life is 20 days).              
 
Despite the above limitations, albumin remains an important indicator of both 
nutritional status and mortality risk. Evidence has shown that plasma albumin is the 
single laboratory finding most closely associated with an increased probability of 
death. The increase in risk is rising modestly at a plasma albumin concentration of 35 
to 39 g/l but being much greater at values below 30g/l (Owen et al, 1993).  
 
5.2.2  nPCR (normalised Protein Catabolic rate) 
The mean nPCR (± SD) of our patients on chronic haemodialysis was 0.82 (±0.20) 
g/kg/day. This is in concordance with the NCDS recommendation of a minimal 
nPCR of 0.8/g/kg/day. In comparison to other countries, it is relatively low: USA 
(1.0 g/kg/day), France (1.12g/kg/day), Spain (1.09g/kg/day), UK (1.03g/kg/day). 
 
5.2.3 BMI (Body Mass Index) 
In our study population, only 5% of patients on chronic haemodialysis were 
underweight (BMI≤18,5kg/m), 65% being in the normal range (BMI between 18,5 to 
24,9kg/m), whereas a significant number of patients (30%) belonged to the zone of 
overweight and obese patients. Fortunately, although obesity confers an increased 
risk of mortality in the general population, observational studies have shown that 
high BMI was associated with increased survival in dialysis patients (Kirsten et al., 
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2004). Moreover the evidence has shown that there is no positive correlation 
between BP and increasing BMI in haemodialysis patients (Abdulla et al, 2004). In 
comparison to the mean BMI (± SD) (23.90±5.07 kg/m2) of our patients on chronic 
haemodialysis, it was found by DOPPS I that the BMI in France and in Italy is 23.2 
and 23.5 kg/m2 respectively, which is almost equal to our patients' BMI (Combe C. 
et al, 2004).  
 
5.2.4 Plasma cholesterol 
Plasma cholesterol levels are lower with ESRD and studies have demonstrated an 
inverse relationship between mortality and cholesterol concentration (Lowrie and 
Lew; 1990).   
 
In the context of cardiovascular risk in patients on chronic haemodialysis, the 
uraemic dyslipidaemic syndrome is characterised by an abnormal lipoprotein profile 
that results in: an elevation of triglyceride rich lipoproteins, very low density 
lipoproteins, intermediate density lipoprotein, and a reduction in high density 
lipoprotein levels. This is very similar to our results where a significant number of 
patients had hypertriglyceridaemia (TG>1,5mmol/l) and low density lipoprotein 
cholesterol (>3mmol/l). As also expected, most of the patients (51%) had low HDL 
cholesterol, and a small number of patients (6%) had a total cholesterol of more than 
5 mmol/l.  
 
Yet, paradoxically, evidence has shown that overweight, hypertension, and 
hyperlipidaemia, which are cardiovascular risk factors in the general population, 
have been reported to correlate with better patient survival in haemodialysis. This 
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might be due to the fact that in patients on haemodialysis, the positive effect of 
higher BMI and hyperlipidaemia but not of hypertension, could be partially 
explained on the basis of the accompanying better nutrition.          
  
4.3. Dialysis dose (Kt/V) and patient outcomes 
 
4.3.1. Dialysis dose (Kt/V) and haemoglobin 
During the study of association between dialysis dose (Kt/V) and haemoglobin, a 
statistically significant correlation was found between the two parameters (p<0.05). 
This result is supported by the evidence that showed that in patients with end stage 
renal disease, inadequate haemodialysis is associated with a suboptimal response to 
erythropoetin therapy. Increasing the intensity of dialysis in patients with anaemia 
who are receiving inadequate dialysis results in a significant increase in the 
haematocrit (Ifudu and Friedman, 1996).  
 
4.3.2. Dialysis dose (Kt/V) and albumin 
During the study, there was no correlation between Kt/V and serum albumin at a 
95% confidence interval, although a correlation was only found at a p-value of 10%. 
This outcome is more or less the same as the HEMO study about the effect of 
dialysis dose and membrane flux on nutritional parameters in haemodialysis patients, 
which showed that while the dose and flux interventions may subtly influence certain 
nutritional parameters, neither intervention prevented deterioration in nutritional 
status over time (Rocco et al, 2004).  
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However, other evidence has demonstrated that daily haemodialysis improves 
nutritional status by increasing serum albumin levels, and arm muscle area (Spanner 
E. et al, 2003). The lack of correlation between dialysis dose and albumin may be 
related to the fact that albumin may change in different circumstances as it is a 
negative acute phase reactant. In this matter, the measurement of CRP (as a marker 
of inflammation) would have helped in reaching a more valid conclusion.   
 
4.3.3. Dialysis dose (Kt/V) and health related quality of life (SF-36) 
 
The SF-36 quality of life scoring system is composed of two dimensions (physical and 
mental) and each one with 5 scales, each of these with 2 scales, which are overlapping 
between the two dimensions.   
 
4.3.3.1. Dialysis dose (Kt/V) and physical dimension     
The correlation between the dialysis dose and physical dimension, one of the two 
components of the two dimensions of the SF-36, was statistically significant (p<0.05) in 2 
of its 5 components and the correlation was also statistically significant (p<0.05) between 
dialysis dose and physical dimension itself which has 5 scales (physical functioning, role 
physical, bodily pain, general health, vitality). The two scales of the physical health to 
which the correlation was positive are physical functioning and role physical. It is 
interesting to find that the correlation was overall statistically significant (p<0.05) between 
dialysis dose and physical health because the correlation was not statistically significant 
(p>0.05) between the dialysis dose and three other scales which are overlapping between 
physical dimension and mental dimension (bodily pain, general health, vitality).  
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4.3.3.2. Dialysis dose (Kt/V) and mental dimension 
The study did not show any correlation (p>0,05) between the dialysis dose (Kt/V) and any 
of the scales of mental health (role emotional, general health, vitality, mental health and 
social functioning). This implies that there are factors other than haemodialysis dose, 
which influence the mental dimension such as primary renal disease, degree of family 
support, financial status (transport, nutrition) etc. 
 
4.3.3.3. Dialysis dose (Kt/V) and overall SF-36 
Nevertheless, the study demonstrated a positive correlation (p<0.05) between dialysis dose 
and the overall scoring results of the SF-36. 
  
All of the above results of the association between dialysis dose and the different 
components can partially be explained by some of the parameters of dialysis adequacy 
which improve with increase of dialysis dose, such as the serum haemoglobin. In fact, 
evidence has confirmed that normalisation of haematocrit/ haemoglobin significantly 
improves the physical and psychosocial dimensions of quality of life and the patient's 
functional self-sufficiency. In fact, the study by Besarab et al, 1998 showed that an 
increase in haematocrit from 30 to 42% was associated with a clinically meaningful 
increase of 7,2 points in the score of the physical function scale (Fuesanta et al, 2000). 
This finding is interesting because our study showed a statistically significant correlation 
between dialysis dose and haemoglobin. This may explain why there was a statistically 
significant correlation between dialysis dose and physical health in particular and its 2 
component scales (physical functioning and role physical). In our study there was a 
statistically significant correlation between dialysis dose and the physical component scale 
(PCS).  
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The above results imply meaningful clinical implications, according to DOPPS data which 
suggest that the HRQOL measures, particularly physical component scale (PCS), have a 
greater capacity to identify patients at risk for death and hospitalisation than serum 
albumin, which has been recognised as a key marker of risk of death among dialysis 
patients. Moreover, HRQOL predicts both shorter- term and longer- term outcomes. In the 
same context of DOPPS results, regardless of whether or not the relationship is causal, the 
data indicates that HRQOL can serve as a sensitive indicator of subsequent patient 
mortality and morbidity (Mapes et al, 2004).  Obviously, if the relationship is causal, then 
interventions that can improve HRQOL might also effectively decrease the risk of death 
and prevent other adverse outcomes in haemodialysis patients. 
However, the study Morton et al, 1996 showed that there is no statistically significant 
association between the dialysis dose (expressed by Kt/V) and any of the domains of 
HRQOL. Thus, HRQL seems to be influenced by factors other than dialysis adequacy, 
enhancing its role as an independent measure of patient problems otherwise undetected by 
traditional objective parameters (Morton et al, 1996).  
 
4.3.3.4. Dialysis dose (Kt/V) and other parameters: 
hospitalisation, sepsis,
 
hypertension 
There was no correlation between dialysis dose (p>0.05) and hospitalisation, despite 
evidence which showed that underdialysed patients have a higher hospitalisation and 
mortality rate (Obialo et al, 1998). Nevertheless, there was a statistically significant 
correlation between dialysis dose (Kt/V) and sepsis, which was among the two main causes 
of hospitalisation in our patient population study. Statistical analysis of the correlation 
between dialysis dose and mortality was not possible in view of the small number of deaths 
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during our study period (4 patients), although, all the patients who passed away had 
inadequate dialysis (Kt/V < 1.2).     
 
Our study of the relationship between dialysis dose and outcomes are not different from 
that of the HEMO study findings, which showed that patients who received a dialysis dose 
higher than the recommended minimum or who used high-flux filters neither lived longer 
nor stayed out of the hospital more than people who received the standard dose or used 
low-flux filters (Rajiv et al, 2004). Obviously, it is not easy to compare the results of the 
HEMO study with our study, because of a significant number of our patients with lower 
than the standard recommended dialysis dose (Kt/V <1.2). At the same time, we did not 
show an effect of dialysis dose on blood pressure control (p>0.05). This differs from other 
studies which showed that increased dialysis dose results in both clinical and laboratory 
improvement regarding hypertension, nutritional status and control of HD patients' 
anaemia (Panagoutsos et al, 2002).    
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CHAPTER 5. CONCLUSION 
 
 
♣ Using the urea kinetic modelling, the indicators of dialysis adequacy on patient 
on chronic haemodialysis in year 2003 were acceptable. In fact the mean 
delivered dialysis dose Kt/V was 1.34 ± 0.25 (K/DOQI recommends a 
minimum of Kt/V = 1.3). 
♣ There are factors responsible for the insufficient delivered haemodialysis dose 
which should be improved, like permanent vascular access creation (AV fistula, 
graft), compliance.  
♣ The other way to improve Kt/V would be either by increasing K (clearance), or 
t (dialysis session length). 
♣ Considering some of the pertinent laboratory markers of dialysis adequacy, our 
study found a relative low mean value of Hb (9.43 ± 1.51 g/dl). This result 
should be improved by ensuring regular supplies of erythropoietin and also by 
providing a sufficient dialysis dose (Kt/V ≥ 1.3) for most of the patients on 
chronic haemodialysis. 
♣ The other important findings from our study which  proves the importance of 
dialysis adequacy was the relationship between dialysis dose and the following 
parameters outcomes: 
♦ The correlation between dialysis dose and Hb was statistically 
significant (p<0.05). 
♦ At the same time the correlation  was also statistically significant 
between dialysis dose and the following markers of quality of life in 
patient on chronic haemodialysis: 
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− Physical dimension 
− Physical functioning 
− Role physical   
− Vitality 
− SF-36 overall results 
       
♦ In addition, the study found the following associations to be statistically 
significant (p<0.05): 
− Dialysis dose (Kt/V) and sepsis 
− Valvular heart disease and duration of haemodialysis 
− Hypertension and diastolic dysfunction, which is a well-known 
association.  
 
♦ It is important to note that all the patients who passed away (4), were 
underdialysed with a Kt/V < 1.2. 
 
♣ In view of all above results of dialysis adequacy and patient outcomes, it is 
important to regularly measure the parameters of dialysis adequacy in order to 
assess whether targets are achieved in accordance with DOQI guidelines, in an 
effort to achieve improved long term outcomes in patients on chronic 
haemodialysis.  
♣ Nevertheless, in view of many contradictions in the studies of dialysis dose and 
related outcomes, randomised multicentre studies are needed for the purpose of 
reviewing the actual guidelines objectively.     
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APPENDIX 1. ETHICS APPROVAL 
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APPENDIX 2. PATIENT INFORMATION SHEET. 
 
 
STUDY TITLE: IMPACT OF DIALYSIS ADEQUACY ON PATIENT 
OUTCOMES. 
 
Hello, my name is Dr KABAHIZI JULES, I am training to be a specialist in the 
Department of Medicine at Wits University. 
I am doing a MMed program, as a part of my training; I am carrying out a study on the 
impact of the amount of dialysis on patient outcomes, such as well being, and 
hospitalisation. 
 
The research involves asking you some questions about your general health, especially 
with regards to the impact of dialysis treatment on your quality of life. The questionnaire 
will take approximately 10 minutes to complete. In addition, I will use the blood results 
obtained from your routine blood tests. The test results and your answers to the questions 
will be kept confidential. These results will be used for my study without disclosing your 
identity. 
 
I invite you to take part in the above study. The participation is voluntarily and you are free 
to agree or refuse to participate. Your treatment will in no way be prejudiced if you refuse 
to participate. 
 
I thank you for your participation, as this study would not be possible without your 
contribution. 
 
 
 
Dr KABAHIZI JULES (Principal investigator) 
 
Prof. S NAICKER (Supervisor) 
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APPENDIX 3. CONSENT FORM 
 
 
I hereby agree to participate in the study entitled: IMPACT OF DIALYSIS ADEQUACY 
ON PATIENT OUTCOMES. 
 
I have read and fully understood the contents of the patient information sheet. I understand 
that the participation in this study is voluntary, and that the results of the study are 
confidential and they may be used for publication. 
 
 
 
-----------------------                             ------------------------                ----------------------- 
  Name of patient                                             Date                                    Signature 
 
 
 
 
--------------------------                       -------------------------               ------------------------- 
 Name of researcher                                         Date                                    Signature 
 
 
 
 
--------------------------                      ----------------------------              --------------------------           
  Name of witness                                            Date                                    Signature 
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APPENDIX 4. Short form 36 Quality of life scales and dimensions. 
 
Note that the vitality and general health scales are overlapping components of both physical 
health and mental health dimensions. Question 2 does not belong to any score, dimension, or the 
total SF-36 scores. It is a self-evaluation of change in health during the past year. 
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APPENDIX 5. Health Survey for Dialysis Patients (SF36)  
            
                        Today’s Date:__________ 
 
Name: Last:____________________  First: _____________  Date of Birth: __________  
 
 
This survey asks for your views about your health.  This information will help keep track of 
how you feel and how well you are able to do your usual activities. 
 
Please answer these questions by “check-marking” your choice. Please select only one 
choice for each item. 
 
1- In general, would you say your health is: 
   1. Excellent   2. Very good   3. Good   4. Fair   5. Poor 
 
 
2- Compared to ONE YEAR AGO, how would you rate your health in general NOW? 
  1. MUCH BETTER than one year ago. 
  2. Somewhat BETTER now than one year ago. 
  3. About the SAME as one year ago. 
  4. Somewhat WORSE now than one year ago. 
  5. MUCH WORSE now than one year ago. 
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3- The following items are about activities you might do during a typical day.  Does your 
health now limit you in these activities? If so, how much? 
Activities 1. Yes, 
Limited 
A Lot 
2.  Yes, 
Limited  
A Little 
3.  No,  
Not Limited 
At All 
a) Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports? 

  
1. Yes, 
limited a lot 
  
2. Yes, 
limited a little 
  
3. No, not 
limited at all 
b) Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing golf? 
  
1. Yes, 
limited a lot 
  
2. Yes, 
limited a little 
  
3. No, not 
limited at all 
c) Lifting or carrying groceries?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
d) Climbing several flights of stairs?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
e) Climbing one flight of stairs?   1. Yes, 
limited a lot
 
  
2. Yes, 
limited a little
 
  
3. No, not 
limited at all
 
f) Bending, kneeing or stooping? 
  
1. Yes, 
limited a lot 
  
2. Yes, 
limited a little 
  
3. No, not 
limited at all 
g) Walking more than a mile? 
  
1. Yes, 
limited a lot 
  
2. Yes, 
limited a little 
  
3. No, not 
limited at all 
h) Walking several blocks?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
i) Walking one block?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
j) Bathing or dressing yourself?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
 
4- During the past 4 weeks, have you had any of the following problems with your work or 
other regular activities as a result of your physical health? 
 Yes No 
a) Cut down on the amount of time you spent on work or 
other activities? 
  
1. yes 
  
2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Were limited in the kind of work or other activities? 
  
1. yes 
  
2. No 
d) Had difficulty performing the work or other activities 
(for example it took extra effort)? 
  
1. yes 
  
2. No 
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5. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
 Yes No 
a) Cut down on the amount of time you spent on work or 
other activities? 

  
1. yes 
  
2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Didn’t do work or other activities as carefully as usual? 
  
1. yes 
  
2. No 
 
 
6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbors, or 
groups? 
  1. Not at all   2. Slightly   3. Moderately       4. Quite a bit       5. Extremely 
 
 
7. How much bodily pain have you had during the past 4 weeks? 
  1. None        2. Very mild       3. Mild       4. Moderate      5. Severe       6. Very 
severe 
 
 
 
8. During the past 4 weeks, how much did pain interfere with your normal work (including 
both work outside the home and housework)? 
  1. Not at all   2. A little bit   3. Moderately       4. Quite a bit       5. Extremely 
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9. These questions are about how you feel and how things have been with you during the 
past 4 weeks.  For each question , please give the one answer that comes closest to the 
way you have been feeling.  How much of the time during the
 past 4 week … 
 1. All of 
the time 
2. Most 
of the 
time 
3. A good 
bit of the 
time 
4. Some 
of the 
time 
5. A little 
of the time 
6. None of 
the time 
a) Did you feel full of pep? 

  
1. All of 
the time
 
  
2. Most 
of the time
 
  
3. A good 
bit of the time
 
  
4. Some 
of the time
 
  
5. A little 
of the time
 
  
6. None of 
the time
 
b) Have you been a very 
nervous person? 
  1. All of 
the time 
  2. Most 
of the time 
  3. A good 
bit of the time 
  4. Some 
of the time 
  5. A little 
of the time 
  6. None of 
the time 
c) Have you felt so down in 
the dumps that nothing could 
cheer you up?  
  1. All of 
the time 
  2. Most 
of the time 
  3. A good 
bit of the time 
  4. Some 
of the time 
  5. A little 
of the time 
  6. None of 
the time 
d) Have you felt calm and 
peaceful? 
  1. All of 
the time 
  2. Most 
of the time 
  3. A good 
bit of the time 
  4. Some 
of the time 
  5. A little 
of the time 
  6. None of 
the time 
e) Did you have a lot of 
energy? 
  1. All of 
the time 
  2. Most 
of the time 
  3. A good 
bit of the time 
  4. Some 
of the time 
  5. A little 
of the time 
  6. None of 
the time 
f) Have you felt downhearted 
and blue? 
  
1. All of 
the time
 
  
2. Most 
of the time
 
  
3. A good 
bit of the time
 
  
4. Some 
of the time
 
  
5. A little 
of the time
 
  
6. None of 
the time
 
g) Do you feel worn out? 
  1. All of 
the time
 
  2. Most 
of the time
 
  3. A good 
bit of the time
 
  4. Some 
of the time
 
  5. A little 
of the time
 
  6. None of 
the time
 
h) Have you been a happy 
person? 
  1. All of 
the time 
  2. Most 
of the time 
  3. A good 
bit of the time 
  4. Some 
of the time 
  5. A little 
of the time 
  6. None of 
the time 
i) Did you feel tired? 
  
1. All of 
the time
 
  
2. Most 
of the time
 
  
3. A good 
bit of the time
 
  
4. Some 
of the time
 
  
5. A little 
of the time
 
  
6. None of 
the time
 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? 
  1. All of the time 
  2. Most of the time. 
  3. Some of the time 
  4. A little of the time. 
  5. None of the time. 
 
 
         
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11. How TRUE or FALSE is each of the following statements for you? 
 1. 
Definitely 
true 
2. 
Mostly 
true 
3.  
Don’t 
know 
4. 
Mostly 
false 
5. 
Definitely 
false 
a) I seem to get sick a little 
easier than other people? 

  1.  
Definitely true 
  2. 
Mostly true 
  3.  
Don’t know  
  4.  
Mostly false 
  5.  
Definitely false 
b) I am as healthy as anybody I 
know? 
  1.  
Definitely true
 
  2. 
Mostly true
 
  3.  
Don’t know 
 
  4.  
Mostly false
 
  5.  
Definitely false
 
c) I expect my health to get 
worse? 
  1.  
Definitely true 
  2. 
Mostly true 
  3.  
Don’t know  
  4.  
Mostly false 
  5.  
Definitely false 
d) My health is excellent? 
  1.  
Definitely true 
  2. 
Mostly true 
  3.  
Don’t know  
  4.  
Mostly false 
  5.  
Definitely false 
  Thank you!  
